

Amendments to the Claims

1. (currently amended) A compound ~~capable of modulating~~ that modulates the activity of a catalytic antibody, wherein said compound ~~being characterized in that it~~ has a specific affinity for ~~the~~ a catalytic site of said antibody, ~~and in that it~~ is non immunogenic, and is a ligand that binds to a receptor.

2.-4. (cancelled)

5. (currently amended) A compound according to ~~any one of claims~~ claim 1 to 3, ~~characterized in that it~~ wherein said compound comprises a peptide derived from the cytokine TNF $\alpha$ , ~~said peptide containing one of the following amino acids sequences: LNRRA, IASVY or LFA.~~

6. (currently amended) A compound according to any one of claims 1 ~~to 3~~ or 24, ~~characterized in that it~~ wherein said compound comprises a peptide derived from thyroglobulin.

7. – 21. (cancelled)

22. (currently amended) A pharmaceutical composition comprising, as the active principle, a compound according to one of ~~claims 1 to 12~~ claim 1 in combination with a pharmaceutically acceptable vehicle.

23. (currently amended) A pharmaceutical composition according to claim 22, ~~characterized in that it further~~ wherein said composition comprises a further active molecule ~~the function of which is to modify or stimulate~~ that modifies or stimulates the biological activity of said compound or ~~to diminish~~ diminishes any secondary effects of said compound.

24. (new) The compound of claim 1, wherein said ligand is a hormone, a drug, or a medication.

Applicant : Alain Friboulet et al.  
Serial No. : 10/716,030  
Filed : November 17, 2003  
Page : 4 of 5

Attorney's Docket No.: 16773-002001 / B4852AF-  
AD/DBO/SZ

25. (new) The compound of claim 5, wherein said peptide comprises amino acid sequence LNRRA (SEQ ID NO: 1).

26. (new) The compound of claim 5, wherein said peptide comprises amino acid sequence IASVY (SEQ ID NO:2).

27. (new) The compound of claim 5, wherein said peptide comprises amino acid sequence LFA.